Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.55% Nasdaq Up0.29%

More On LOR.TO



News & Info


Analyst Coverage


  • Major Holders
  • Insider Transactions
  • Insider Roster


Lorus Therapeutics Inc. (LOR.TO)

0.50 Up 0.02(4.17%) Apr 15
Get the big picture on all your investments.
ProfileGet Profile for:
Lorus Therapeutics Inc.
2 Meridian Road
Toronto, ON M9W 4Z7
Canada - Map
Phone: 416-798-1200
Fax: 416-798-2200

Index Membership:N/A
Full Time Employees:15

Business Summary 

Lorus Therapeutics Inc., a biopharmaceutical company, engages in the discovery, research, and development of novel anticancer therapies in Canada. Its product pipeline includes LOR-253, an anticancer agent for the treatment of human cancers, including colon cancer and non-small cell lung cancer; IL-17E, an immunotherapy for various solid tumors, including human melanoma, pancreatic, colon, lung, ovarian, and breast tumor; and LOR-500 program to discover and develop potent and small molecule inhibitors of maternal embryonic leucine zipper kinase. The company’s development stage products also include LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor for the treatment of acute myeloid leukemia; and Virulizin for various cancers, including breast, ovarian, and pancreatic cancers. In addition, its preclinical stage small molecules comprise LOR-220, a novel small molecule for drug-resistant bacterial infections. The company was formerly known as Imutec Pharma Inc. and changed its name to Lorus Therapeutics Inc. in November 1998. Lorus Therapeutics Inc. was founded in 1986 and is headquartered in Toronto, Canada.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Lorus Therapeutics Inc.

Key Executives 
Dr. William G. Rice Ph.D.,
Chairman, Chief Exec. Officer and Pres
Ms. Elizabeth Williams CA,
Acting Chief Financial Officer, Principal Accounting Officer, Director of Fin. and Controller
Mr. Gregory K. Chow CPA, MBA, BA,
Chief Financial Officer and Sr. VP
Mr. Avanish Vellanki MBA, MBS, BA,
Chief Bus. Officer and Sr. VP
Dr. Daniel Douglas Von Hoff M.D., F.A.C.P., 66
Sr. VP of Medical Affairs
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.